Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LERCANIDIPINE Cause International normalised ratio increased? 5 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of International normalised ratio increased have been filed in association with LERCANIDIPINE. This represents 0.1% of all adverse event reports for LERCANIDIPINE.

5
Reports of International normalised ratio increased with LERCANIDIPINE
0.1%
of all LERCANIDIPINE reports
0
Deaths
0
Hospitalizations

How Dangerous Is International normalised ratio increased From LERCANIDIPINE?

Of the 5 reports, and 5 (100.0%) were considered life-threatening.

Is International normalised ratio increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LERCANIDIPINE. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does LERCANIDIPINE Cause?

Acute kidney injury (424) Hypotension (401) Fall (323) Hypertension (197) Hyperkalaemia (176) Drug ineffective (149) Diarrhoea (122) Hyponatraemia (122) Renal impairment (120) Oedema peripheral (114)

What Other Drugs Cause International normalised ratio increased?

WARFARIN (5,622) RIVAROXABAN (863) ACETAMINOPHEN (533) ASPIRIN (448) APIXABAN (317) CLOPIDOGREL BISULFATE (314) FLUINDIONE (286) AMIODARONE (277) FUROSEMIDE (277) DABIGATRAN ETEXILATE (223)

Which LERCANIDIPINE Alternatives Have Lower International normalised ratio increased Risk?

LERCANIDIPINE vs LETAIRIS LERCANIDIPINE vs LETERMOVIR LERCANIDIPINE vs LETROZOLE LERCANIDIPINE vs LETROZOLE\RIBOCICLIB LERCANIDIPINE vs LEUCOVORIN

Related Pages

LERCANIDIPINE Full Profile All International normalised ratio increased Reports All Drugs Causing International normalised ratio increased LERCANIDIPINE Demographics